Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin Academic Article Article uri icon

Overview

MeSH Major

  • Carcinoma, Squamous Cell
  • Combined Modality Therapy
  • Head and Neck Neoplasms
  • Maximum Tolerated Dose

abstract

  • Vaccination with NP-polySA-KLH, but not polySA-KLH, resulted in a consistent high titer antibody response. We are now conducting a de-escalation dosing study with NP-polySA-KLH to better assess the immunogenicity, toxicities, and optimal dose of this vaccine. We plan to incorporate this vaccine as a component of a polyvalent vaccine with GM2, fucosylated GM1, and Globo H to target SCLC.

publication date

  • February 2004

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-03-0101

PubMed ID

  • 14871967

Additional Document Info

start page

  • 916

end page

  • 23

volume

  • 10

number

  • 3